12:00 AM
Nov 19, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Status

Tradjenta: Completed Phase III enrollment

The partners completed enrollment of >6,000 Type II diabetics at high cardiovascular risk in the double-blind, international Phase III CAROLINA trial comparing 5 mg oral linagliptin once daily vs. 1-4 mg oral glimepiride once daily. The partners said the trial is the first...

Read the full 192 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >